Eledon Pharmaceuticals (ELDN) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
12 Nov, 2026Executive summary
Tegoprubart, an anti-CD40L antibody, remains the focus of development in kidney and islet transplantation; no products are approved and no product sales revenue has been generated.
Q3 net loss narrowed to $3.9M from $17.5M, mainly due to a $17.0M non-cash warrant-liability fair-value gain; operating expenses increased to $21.7M.
Kidney-transplant extension data showed higher eGFR with tegoprubart than tacrolimus through month 24; planned registrational trials remain dependent on additional financing.
Financial highlights
Q3 R&D expense was $17.8M vs. $15.0M a year earlier; G&A was $3.9M vs. $4.1M, and operating expenses totaled $21.7M vs. $19.1M.
Q3 net loss was $3.9M, or $0.03 per share, vs. $17.5M, or $0.21 per share; excluding warrant fair-value changes, Q3 net loss was $21.0M vs. $18.0M.
9M operating expenses were $65.7M vs. $61.8M, and net loss was $74.6M vs. $35.2M; warrant remeasurement shifted from a $22.9M gain to an $11.6M loss.
9M operating cash use was $64.3M vs. $48.3M; quarter-end cash and equivalents were $6.9M, while cash, equivalents and short-term investments totaled $69.7M.
Outlook and guidance
Global Phase 3 LEGACY in kidney transplantation is planned for Q4 2026, subject to financing; expected enrollment is ~600, with a week-52 non-inferiority endpoint based on BPAR, graft loss and death.
FDA cleared the IND for a planned company-sponsored registrational-path islet-transplant study; initiation requires additional financing.
Other planned programs include an investigator-led de novo liver-transplant study; FDA guidance on the kidney xenotransplantation path to market is anticipated over the next 12 months.
Manufacturing and personnel costs are expected to rise as kidney Phase 3 and islet programs advance; current resources are not expected to fund planned operations for at least 12 months from financial-statement issuance.
Latest events from Eledon Pharmaceuticals
- Tegoprubart shows superior efficacy and safety over tacrolimus in transplant trials.ELDN
Corporate presentation - Net loss rose to $31.6M in Q2 2026; strong clinical data but further funding required.ELDN
Q2 2026 - Phase 2 kidney transplant data and islet cell trial results expected next year, backed by strong funding.ELDN
Guggenheim Securities Inaugural Healthcare Innovation Conference - Tegoprubart advances with robust transplant data, global trials, and broad expansion potential.ELDN
Leerink’s Global Healthcare Conference 2025 - Tegoprubart delivers superior kidney function, safety, and quality of life compared to tacrolimus.ELDN
Study result - Tegoprubart achieved key clinical results; Q1 2026 net loss $39.0M, cash runway into Q2 2027.ELDN
Q1 2026 - Biotech firm seeks to raise up to $500M, including $75M at-the-market, for immunology R&D.ELDN
Registration filing - Shareholders will vote on director elections, share authorization, and auditor ratification.ELDN
Proxy filing - Shareholders will vote on director elections, stock authorization increase, and auditor ratification.ELDN
Proxy filing